Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2020-10-13 Regulatory Filings
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 13, 2020, by AnaptysBio, Inc. It announces positive topline data from a Phase 2 clinical trial and includes a press release as an exhibit. The document is relatively short (4094 characters) and primarily serves as a current report to disclose material events or corporate changes. It does not contain detailed financial statements or comprehensive financial analysis. Form 8-K filings are regulatory filings used to report significant events and are not annual or quarterly reports, earnings releases, or other detailed financial documents. Therefore, this document fits best under the category of Regulatory Filings (RNS).
2020-10-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a termination notice of a material definitive agreement and related legal proceedings, including a breach notice and a complaint filed in court. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a significant corporate event and legal action. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-08-20 English
10-Q
Interim / Quarterly Report Q2 2020
2020-08-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2020, by AnaptysBio, Inc. It announces financial results for the six months ended June 30, 2020, and includes press releases as exhibits. The document is a current report providing updates on financial results and clinical trial data, not a full annual or quarterly report. It is a regulatory filing used to disclose material events promptly. The document length is 4605 characters, which is relatively short and consistent with an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain full financial statements or detailed analysis typical of an Interim Report or Annual Report.
2020-08-10 English
FORM 4 SUBMISSION
Director's Dealing
2020-07-31 English
FORM 3 SUBMISSION
Director's Dealing
2020-07-31 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.